08.27.24 -- Clinical Trials In China Reboot BIOSECURE Act

Our EMEA Advance Biotech Grant Program is open for European biotech startup companies to help them accelerate to clinic faster. Enter for a chance to win €148,400 in products & services. Learn more here.

“We tell them up front we will be hands on. That's a good way to pick the right partners. In other words, we select and view our CDMOs based on the way we operate," explains BlueSphere Bio CEO Keir Loiacono. With a background as an attorney, it's an interesting outsourcing operations indeed.

Gene therapy products are complicated, and it can be hard to know at which step to measure potency. Here's how CSL Behring did it for Hemgenix.

Combined with the inherent difficulty of the chemistry behind gene therapy development, its pace, structure, and funding dynamics are unique among treatment modalities.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

As mRNA medicine continues to evolve, understand how trusted manufacturing partners will continue to play a pivotal role in translating innovative concepts into clinical reality.

When it comes to furthering AAV's potential in the biopharma pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

By utilizing an engineered co-transcriptional capping RNA Polymerase, researchers can reduce dsRNA byproducts and enhance the functionality of mRNA therapeutics.

Industry experts answer attendee questions from a recent webinar about sustainability concerns surrounding oligonucleotide manufacturing.

Innovative supply chain solutions can help companies mitigate risk to their overall supply chain while saving valuable capital for the research of their lifesaving therapies.

RNA therapeutics hold promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and timelines can help reduce costs.

We have a powerful suite of proprietary gene editing technologies to accelerate the development of life-changing and curative therapies for patients.

As a CDMO Partner for Life, our goal is to advance your cell therapies from lab to commercial scale, leveraging our CGT expertise and global cGMP network.

The UpTempo AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current development timeline for drug product in half.

Review Pfizer CentreOne’s overall gene & cell therapy capabilities, with a focus on their ability to help meet your complex viral vector needs.

Our microbial team is dedicated to providing solutions in pDNA manufacturing, including long terminal repeat (LTR)-containing plasmids, for gene and cell therapy developers.

Learn how our cryopreservation services are enabling hospital, biotech, and pharma clients to safely preserve and store valuable cellular products, tissues, and biomaterials.